Avatrombopag - Swedish Orphan Biovitrum
Alternative Names: AKR-501; AKR-501 monomaleate; Avatrombopag maleate; DOPTELET; E-5501; Su Ke Xin; YM-477Latest Information Update: 31 Dec 2024
At a glance
- Originator Astellas Pharma
- Developer Dova Pharmaceuticals; Eisai Co Ltd; Shanghai Fosun Pharmaceutical; Swedish Orphan Biovitrum
- Class Antithrombotics; Piperazines; Piperidines; Pyridines; Small molecules; Thiazoles
- Mechanism of Action Thrombopoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Idiopathic thrombocytopenic purpura; Thrombocytopenia
Most Recent Events
- 12 Dec 2024 Preregistration for Thrombocytopenia in USA (PO, Suspension)
- 12 Dec 2024 Efficacy and adverse events data from a phase-III clinical trials in Thrombocytopenia released by Swedish Orphan Biovitrum
- 12 Dec 2024 Preregistration for Thrombocytopenia (In children, In adolescents, In infants, Treatment-experienced) in USA (PO)